301 related articles for article (PubMed ID: 35694999)
1. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
Lasagna A; Lenti MV; Cassaniti I; Sacchi P
Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
Kang SH; Kim MY; Cho MY; Baik SK
J Korean Med Sci; 2022 Apr; 37(15):e116. PubMed ID: 35437965
[TBL] [Abstract][Full Text] [Related]
3. First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination.
Mahalingham A; Duckworth A; Griffiths WJH
Transpl Immunol; 2022 Jun; 72():101600. PubMed ID: 35390478
[TBL] [Abstract][Full Text] [Related]
4. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
Efe C; Kulkarni AV; Terziroli Beretta-Piccoli B; Magro B; Stättermayer A; Cengiz M; Clayton-Chubb D; Lammert C; Bernsmeier C; Gül Ö; la Tijera FH; Anders M; Lytvyak E; Akın M; Purnak T; Liberal R; Peralta M; Ebik B; Duman S; Demir N; Balaban Y; Urzua Á; Contreras F; Venturelli MG; Bilgiç Y; Medina A; Girala M; Günşar F; Londoño MC; Androutsakos T; Kisch A; Yurci A; Güzelbulut F; Çağın YF; Avcı E; Akyıldız M; Dindar-Demiray EK; Harputluoğlu M; Kumar R; Satapathy SK; Mendizabal M; Silva M; Fagiuoli S; Roberts SK; Soylu NK; Idilman R; Yoshida EM; Montano-Loza AJ; Dalekos GN; Ridruejo E; Schiano TD; Wahlin S
Hepatology; 2022 Dec; 76(6):1576-1586. PubMed ID: 35567545
[TBL] [Abstract][Full Text] [Related]
5. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination.
Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A
Front Immunol; 2022; 13():908108. PubMed ID: 35911701
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
7. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
9. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination.
Vuille-Lessard É; Montani M; Bosch J; Semmo N
J Autoimmun; 2021 Sep; 123():102710. PubMed ID: 34332438
[TBL] [Abstract][Full Text] [Related]
13. Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models.
Zirkenbach VA; Ignatz RM; Öttl R; Cehreli Z; Stroikova V; Kaya M; Lehmann LH; Preusch MR; Frey N; Kaya Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902442
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
Strobel SB; Machiraju D; Kälber KA; Hassel JC
Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.
Lemoine C; Padilla C; Krampe N; Doerfler S; Morgenlander A; Thiel B; Aggarwal R
Clin Rheumatol; 2022 May; 41(5):1597-1601. PubMed ID: 35294664
[TBL] [Abstract][Full Text] [Related]
18. New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review.
Nakazawa E; Uchimura T; Hirai Y; Togashi H; Oyama Y; Inaba A; Shiga K; Ito S
CEN Case Rep; 2022 May; 11(2):242-246. PubMed ID: 34782983
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by COVID-19 mRNA Vaccine (Pfizer-BioNTech, BNT162b2): A Case Report and Literature Review.
Kim JH; Chae HB; Woo S; Song MS; Kim HJ; Woo CG
Int J Surg Pathol; 2023 Sep; 31(6):1156-1162. PubMed ID: 37272061
[TBL] [Abstract][Full Text] [Related]
20. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine.
Abi Zeid Daou C; Natout MA; El Hadi N
J Med Virol; 2021 Oct; 93(10):6027-6029. PubMed ID: 34050949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
